This follows a period of company creation, with seed investment and close involvement by Arix.
Led by a team of drug developers and scientists with deep experience in inflammation and small molecule drug discovery, Quench Bio's lead therapeutic approach centres on inhibiting the protein Gasdermin D, which has recently been discovered as a key target at the core of multiple inflammatory cell death pathways, including pyroptosis and NETosis. This is at the cutting edge of contemporary drug development and a field of significant commercial interest by big pharma.
The company has built a highly experienced leadership team, led by Chief Executive Officer
Arix and
In addition to Arix and its co-founding investor
'We are excited and privileged to work alongside such a distinguished team of entrepreneurs and co-investors to develop first-in-class medicines that could make a major difference to patients suffering from chronic inflammatory and auto-immune diseases. The genesis of Quench originated from our long-standing relationship with the
'The successful financing underscores the potential of our innovative approach. We are delighted by the strong support from Arix as well as our existing and new investors and I look forward to leveraging their extensive experience as we develop multiple programs to target severe inflammatory diseases.'
Contact:
Tel: +44 (0)20 7290 1050
Email: info@arixbioscience.com
(C) 2020 Electronic News Publishing, source